

# Oncimmune

15:06 22 Nov 2019

## Oncimmune has "substantially reduced" commercial risk for EarlyCDT cancer test, says broker

Oncimmune Holdings PLC (LON:ONC) has "substantially reduced" the commercial launch risk for its EarlyCDT lung cancer test through a series of supply and licence deals, according to analysts at finnCap.

In a note initiating the biotech firm with a price target of 150p, the broker said the company's business model reduced execution risk through supply and licence deals in the US and China, distribution agreements in 23 additional markets and "a diversifying pipeline of revenues".

**READ:** Oncimmune Holdings draws down final tranche of IPF facility  
As a result, they expected "early evidence of the revenue ramp" in the current year, predicting £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half.


finnCap also expects Oncimmune to be cash flow positive by 2024, while its current cash balance, which provides funds until 2022, would provide "the time to deliver further meaningful valuation points".

In late-afternoon trading on Friday, Oncimmune shares were 1% higher at 51p, a 66% discount to finnCap's target price.

**Price:** 37

**Market Cap:** £23.4 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** ONC

**Listing:** AIM

**52 week High Low**  
115 36

**Sector:** Pharma & Biotech

**Website:** oncimmune.com

### Company Synopsis:

*Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).